Post-earnings recap
Reported
Wed, Feb 9, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Viking Therapeutics reported a narrower loss than expected, which contributed to a positive stock reaction, with shares rising by 3.9%. The company did not provide revenue figures or future guidance, leaving investors focused on the EPS beat. Management's comments suggest a steady commitment to their clinical programs, which may reassure investors about the company's direction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.16 | N/A | +15.79% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the company's current trajectory and emphasized their commitment to ongoing clinical development.
We are pleased with our progress in the quarter.
Our focus remains on advancing our clinical programs.